The cost pressure on biopharmaceuticals drives the industry toward exploring process intensification options that will maintain or improve quality, stability, and manufacturability of the product while increasing productivity. One such option explored is continuous, or connected, biomanufacturing. For continuous chromatography, interest in techniques such as periodic counter current chromatography (PCC) is increasing.
In this poster presented at the Recovery XVIII conference, based on data from a collaboration between Merck and Cytiva, we use two case studies to demonstrate that PCC is a robust and scalable technology: a 50-fold scale-up of a three-column PCC (3C PCC) mAb capture step within the lab-scale ÄKTA™ pcc system and a 294-fold scale-up directly from lab to manufacturing scale.